The Anthrax Spore Vaccine Facility specializes in the large-scale production of the Anthrax Spore Vaccine used to immunize cattle, sheep, and goats against anthrax. The vaccine is based on the Sterne strain (34F2) of Bacillus anthracis, known for its safety and effectiveness.
All stages of production, from seed culture to lyophilization and final packaging, are conducted under aseptic and controlled environmental conditions in compliance with national veterinary biological standards.
The facility is equipped with high-level biosafety infrastructure including:
The facility continuously works on enhancing vaccine stability, improving production yield, and exploring recombinant antigen-based anthrax vaccine formulations. Collaboration with national biosafety and veterinary research centers supports ongoing innovation.
Every batch of vaccine is tested for viability, purity, and safety as per the Indian Veterinary Biological Standards. Quality audits and process validations ensure the product meets regulatory and international standards.